Furihata M, Sonobe H, Ohtsuki Y, Yamashita M, Morioka M, Yamamoto A, Terao N, Kuwahara M, Fujisaki N
Department of Pathology II, Kochi Medical School, Nankoku, Japan.
J Pathol. 1996 Feb;178(2):133-9. doi: 10.1002/(SICI)1096-9896(199602)178:2<133::AID-PATH455>3.0.CO;2-F.
Ninety-four patients with transitional cell carcinoma (TCC) of the renal pelvis and ureter, including dysplastic lesions, were studied for p53 and bcl-2 protein expression by immunohistochemistry. Twenty-one patients were also studied for p53 gene mutations by direct sequencing and for bcl-2 gene rearrangement by Southern blot analysis. Overexpressed p53 protein was detected in 26 cases (27.7 per cent). bcl-2 immunostaining was observed in 21 tumours (22.3 per cent), including four cases with labelling for p53. Furthermore, the dysplastic lesions surrounding 19 p53-positive tumours also stained for p53. bcl-2 expression was also detected frequently in dysplastic lesions adjacent to 14 bcl-2-positive TCCs. Positive reactions of dysplastic lesions were also found adjacent to 37 bcl-2-negative tumours. p53 point mutation was detected in 6 of 21 cases. Five of the six cases were positive for p53 protein. blc-2 positivity was detected in 3 of 21 tumours, without bcl-2 gene rearrangements in the major breakpoint region. Overexpressed p53 protein was frequently detected in both high-grade (P < 0.05) and invasive tumours (P < 0.05). In three cases of p53-positive non-papillary invasive tumours, bcl-2 was found in non-invasive portions, but was not present in invasive areas. These findings suggest that overexpression (mutation) of p53 and/or bcl-2 protein may be early events in tumourigenesis and that p53 alterations in particular are essential for the maintenance of a malignant phenotype in tumour development.
对94例肾盂和输尿管移行细胞癌(TCC)患者(包括发育异常病变)进行免疫组织化学研究,检测p53和bcl-2蛋白表达。对21例患者还进行了直接测序检测p53基因突变以及Southern印迹分析检测bcl-2基因重排。26例(27.7%)检测到p53蛋白过表达。21例肿瘤(22.3%)观察到bcl-2免疫染色,其中4例同时有p53标记。此外,19例p53阳性肿瘤周围的发育异常病变也呈p53染色阳性。在14例bcl-2阳性TCC相邻的发育异常病变中也经常检测到bcl-2表达。在37例bcl-2阴性肿瘤相邻处也发现发育异常病变呈阳性反应。21例中有6例检测到p53点突变。6例中的5例p53蛋白呈阳性。21例肿瘤中有3例检测到bcl-2阳性,但主要断裂点区域未发现bcl-2基因重排。在高级别肿瘤(P<0.05)和浸润性肿瘤(P<0.05)中均经常检测到p53蛋白过表达。在3例p53阳性的非乳头状浸润性肿瘤中,bcl-2在非浸润部分存在,但浸润区域未出现。这些发现表明,p53和/或bcl-2蛋白的过表达(突变)可能是肿瘤发生的早期事件,尤其是p53改变对于肿瘤发展中恶性表型的维持至关重要。